Nuvation Bio Inc. (NUVB) Operating Margin
- Operating margin · 12 months: Value -81.00%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -81.00% | Operating income / revenue. Period ending 2026-06-30. $-137.63M ÷ $169.90M × 100 ≈ -81.00% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -137.63M USD | Operating Income (Loss) |
| Revenue | 169.90M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 128.85M USD | Research and Development Expense |
| Selling, general and administration | 158.59M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-137.63M | $169.90M | (m) | $128.85M | $158.59M | -81.00% |
| 2026-03-31 | $-150.18M | $143.05M | (m) | $125.55M | $154.48M | -104.99% |
| 2025-12-31 | $-213.06M | $62.90M | (m) | $115.11M | $151.56M | -338.72% |
| 2025-09-30 | $-232.97M | $26.75M | $12.23M | $110.11M | $137.37M | -870.98% |
| 2025-06-30 | $-224.64M | $14.36M | $10.40M | $108.99M | $119.60M | -1564.86% |
| 2025-03-31 | $-631.43M | $10.96M | $9.17M | $110.88M | $97.27M | -5762.82% |
| 2024-12-31 | $-592.63M | $7.87M | $7.08M | $99.12M | $69.23M | -7527.33% |
| 2024-09-30 | $-559.52M | (m) | (m) | $85.17M | (m) | (m) |
| 2024-06-30 | $-537.75M | (m) | (m) | $76.00M | (m) | (m) |
| 2024-03-31 | $-93.50M | (m) | (m) | $65.34M | (m) | (m) |
| 2023-12-31 | $-99.82M | (m) | (m) | $71.29M | (m) | (m) |
| 2023-09-30 | $-103.33M | (m) | (m) | $72.81M | (m) | (m) |
| 2023-06-30 | $-106.33M | (m) | (m) | $75.54M | (m) | (m) |
| 2023-03-31 | $-118.06M | (m) | (m) | $85.87M | (m) | (m) |
| 2022-12-31 | $-119.73M | (m) | (m) | $87.81M | (m) | (m) |
| 2022-09-30 | $-125.01M | (m) | (m) | $92.95M | (m) | (m) |
| 2022-06-30 | $-118.46M | (m) | (m) | $88.77M | (m) | (m) |
| 2022-03-31 | $-101.03M | (m) | (m) | $73.89M | (m) | (m) |
| 2021-12-31 | $-93.32M | (m) | (m) | $69.04M | (m) | (m) |
| 2021-09-30 | $-66.03M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-43.98M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |